MCID: CHL066
MIFTS: 52

Cholangitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis 12 30 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9446
ICD9CM 36 576.1
MeSH 45 D002761
NCIt 51 C26718
SNOMED-CT 69 82403002
ICD10 34 K83.0
UMLS 74 C0008311

Summaries for Cholangitis

Disease Ontology : 12 A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary : Cholangitis is related to sclerosing cholangitis, neonatal and suppurative cholangitis. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and colon, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Acute Cholangitis Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 34.2 CLDN1 DCDC2
2 suppurative cholangitis 33.2 ABCB4 CRP DLAT TNF
3 cholangitis, primary sclerosing 33.2 ABCB4 ALB CFTR DLAT FUT2 GGT1
4 sclerosing cholangitis 32.8 ABCB4 ALB CFTR CLDN1 DCDC2 FUT2
5 cholecystitis 32.4 ABCB4 ALB F2 GPT
6 cholelithiasis 32.1 ABCB4 ALB GPT NR1H4
7 autoimmune pancreatitis 31.2 CA2 CFTR HLA-DRB1
8 hepatitis 31.1 CLDN1 F2 GGT1 GPT TNF
9 autoimmune hepatitis 31.0 DLAT F2 GGT1 GPT HLA-DRB1
10 biliary atresia 30.9 ALB GPT NR1H4
11 acquired immunodeficiency syndrome 30.4 ALB IL6 TNF
12 choledocholithiasis 30.4 ABCB4 ALB ALPP F2 GPT
13 infantile liver failure syndrome 1 30.4 ALB F2 GPT
14 echinococcosis 30.3 HLA-DRB1 IL6 TNF
15 liver cirrhosis 30.2 ALB F2 GGT1 GPT
16 hepatitis c 30.2 CLDN1 GGT1 GPT TNF
17 portal hypertension 30.2 ALB F2 GPT TNF
18 bilirubin metabolic disorder 30.2 ALB F2 GGT1 GPT
19 graft-versus-host disease 30.2 HLA-DRB1 IL6 TNF
20 fascioliasis 30.0 ALB ALPP GPT
21 acute pancreatitis 29.9 CFTR CRP IL6
22 hepatitis a 29.9 ALB F2 GPT TNF
23 cholestasis 29.9 ABCB4 ALPP F2 GGT1 GPT NR1H4
24 acute liver failure 29.9 ALB F2 GPT
25 intussusception 29.9 CFTR CRP IL6
26 hepatitis b 29.8 ALB F2 GGT1 GPT TNF
27 angioimmunoblastic lymphadenopathy with dysproteinemia 29.8 IL6 TNF
28 hepatitis e 29.7 ALB F2 GPT TNF
29 cystitis 29.5 CRP IL6 TNF
30 psoriatic arthritis 29.5 CRP HLA-DRB1 IL6 TNF
31 kawasaki disease 29.4 ALB CRP IL6 TNF
32 purpura 29.4 CRP F2 IL6 TNF
33 meningitis 29.3 ALB CRP IL6 TNF
34 acute cystitis 29.3 ALB CRP IL6
35 acute pyelonephritis 29.3 ALB CRP IL6
36 gastroenteritis 29.3 ALB CRP FUT2 IL6 TNF
37 myeloma, multiple 29.2 ALB CRP IL6 TNF
38 chlamydia 29.2 CRP IL6 TNF
39 bronchiolitis 29.2 CRP IL6 TNF
40 bacterial infectious disease 29.1 CFTR CRP IL6 TNF
41 pyelonephritis 29.1 ALB CRP IL6 TNF
42 bacterial meningitis 29.1 ALB CRP IL6 TNF
43 liver disease 29.1 ABCB4 ALB ALPP DLAT F2 GGT1
44 leptospirosis 29.0 CRP F2 IL6 TNF
45 biliary tract disease 29.0 ABCB4 ALB CEACAM5 F2 GGT1 GPBAR1
46 peritonitis 28.8 ALB CRP F2 IL6 TNF
47 bile duct disease 28.8 ABCB4 ALB CEACAM5 F2 GGT1 GPBAR1
48 systemic lupus erythematosus 28.8 ALB CRP F2 HLA-DRB1 IL6 TNF
49 heart disease 28.8 ALB CRP F2 IL6 TNF
50 obstructive jaundice 28.8 ALB ALPP CRP F2 GGT1 GPBAR1

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Acute Pancreatitis
Cholecystitis Cholestasis
Deficiency Anemia Familial Atrial Fibrillation
Gallbladder Cancer Heart Disease
Hepatitis Intrahepatic Gall Duct Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Postcholecystectomy Syndrome
Primary Biliary Cirrhosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:



Diseases related to Cholangitis

Symptoms & Phenotypes for Cholangitis

MGI Mouse Phenotypes related to Cholangitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.97 ABCB4 ALB CA2 CFTR F2 FUT2
2 homeostasis/metabolism MP:0005376 9.93 ABCB4 ALB CA2 CFTR CLDN1 CRP
3 endocrine/exocrine gland MP:0005379 9.91 ABCB4 ALB CA2 CFTR GGT1 GPBAR1
4 immune system MP:0005387 9.7 ABCB4 CA2 CFTR CRP F2 FUT2
5 liver/biliary system MP:0005370 9.17 ABCB4 ALB CFTR GPBAR1 IL6 NR1H4

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
3
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
4
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 441141 14969
5
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
8
Azithromycin Approved Phase 4 83905-01-5 55185 447043
9
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
10
Cefotaxime Approved Phase 4,Not Applicable 63527-52-6 456256 5742673
11
Cefoxitin Approved Phase 4,Not Applicable 35607-66-0 441199
12
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
13
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
14
Metronidazole Approved Phase 4,Phase 1,Not Applicable 443-48-1 4173
15
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
16
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
17
Prednisolone phosphate Approved, Vet_approved Phase 4,Not Applicable 302-25-0
18
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
19
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 4,Not Applicable 2921-57-5
21
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492 6473866
22
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
23
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 128-13-2 31401
24
chenodeoxycholic acid Approved Phase 4,Phase 3,Phase 2 474-25-9 10133
25
Temocillin Approved, Investigational Phase 4 66148-78-5
26
Palonosetron Approved, Investigational Phase 4 135729-61-2, 119904-90-4, 135729-56-5 148211
27
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
28
Fosaprepitant Approved Phase 4 172673-20-0 219090
29
Prednisolone hemisuccinate Experimental Phase 4,Not Applicable 2920-86-7
30
Substance P Investigational Phase 4 33507-63-0 44359816
31 Cytochrome P-450 Enzyme Inhibitors Phase 4
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
36 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
37 Anti-Infective Agents, Urinary Phase 4
38 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Renal Agents Phase 4
40 Amoxicillin-Potassium Clavulanate Combination Phase 4
41 Epinephryl borate Phase 4,Not Applicable
42 Adrenergic alpha-Agonists Phase 4,Not Applicable
43 Adrenergic Agents Phase 4,Not Applicable
44 Respiratory System Agents Phase 4,Phase 2,Phase 1,Not Applicable
45 Bronchodilator Agents Phase 4,Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
47 Sympathomimetics Phase 4,Not Applicable
48 Adrenergic Agonists Phase 4,Not Applicable
49 Vasoconstrictor Agents Phase 4,Phase 2,Not Applicable
50 Autonomic Agents Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 278)
# Name Status NCT ID Phase Drugs
1 Antibiotics to Decrease Post ERCP Cholangitis Unknown status NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
2 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
3 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
4 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
6 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
7 Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction Completed NCT02909595 Phase 4
8 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
9 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
10 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
11 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Completed NCT02057679 Phase 4 Amoxicillin clavulanic;Placebo
12 A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients. Completed NCT00545402 Phase 4 Mycophenolate mofetil, adjusted dose;Tacrolimus;Corticosteroids, IV;Mycophenolate mofetil, Standard dose;Corticosteroids, PO
13 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
14 Leflunomide for Maintenance of Remission in IgG4 Related Disease Completed NCT02703194 Phase 4 Prednisone;Leflunomide
15 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
16 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
17 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
18 Temocillin Pharmacokinetics in Paediatrics Recruiting NCT02260102 Phase 4 Temocillin
19 PALONOSETRON X FOSAPREPITANT IN PONV Recruiting NCT03586817 Phase 4 Palonosetron;Fosaprepitant
20 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
21 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
22 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
23 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
24 Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones Unknown status NCT01425177 Phase 3
25 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
26 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
27 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
28 Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients Completed NCT00622869 Phase 3 Tacrolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Everolimus (reduced tacrolimus);Everolimus (tacrolimus elimination);Corticosteroids
29 Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients Completed NCT01150097 Phase 3 Tacrolimus (reduced tacrolimus);Everolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Everolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Corticosteroids
30 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Completed NCT02550288 Phase 3 Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
31 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Completed NCT02460159 Phase 3 EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
32 A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832) Completed NCT02741245 Phase 3 Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
33 A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients Completed NCT01625377 Phase 3 tacrolimus;everolimus;Basiliximab;Mycophenolic Acid;Corticosteroids
34 ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Recruiting NCT03602560 Phase 3 seladelpar 5-10 mg;seladelpar 10 mg;Placebo
35 Vancomycin for Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
36 Norursodeoxycholic Acid vs Placebo in PSC Recruiting NCT03872921 Phase 3 Norursocholic Acid
37 Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 2, Phase 3 Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
38 Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Recruiting NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
39 Kaffes Stent in the Management of Post-surgical Biliary Strictures Recruiting NCT03716232 Phase 3
40 Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation Recruiting NCT02584283 Phase 3 Glutathione
41 A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma Recruiting NCT02539537 Phase 3 Gemcitabine;Folinic Acid;5-Fluoro-uracil;Oxaliplatin;Irinotecan;L-folinic
42 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
43 Remaxol® in Malignant Mechanical Jaundice Recruiting NCT03416062 Phase 3 Remaxol®;Ringer's Solution
44 Remaxol® in Mechanical Jaundice of Non-malignant Origin Recruiting NCT03418935 Phase 3 Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
45 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Active, not recruiting NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
46 Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PSC-Phase 3) Not yet recruiting NCT03890120 Phase 3 GS-9674;Placebo
47 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
48 Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice Unknown status NCT01275768 Phase 1, Phase 2
49 Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis Unknown status NCT01690845 Phase 2
50 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Completed NCT02653625 Phase 2 Cenicriviroc 150 mg

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Genetic Tests for Cholangitis

Genetic tests related to Cholangitis:

# Genetic test Affiliating Genes
1 Cholangitis 30

Anatomical Context for Cholangitis

MalaCards organs/tissues related to Cholangitis:

42
Liver, T Cells, Colon, Neutrophil, Bone, Pancreas, Testes

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 4144)
# Title Authors Year
1
Short-Course Antibiotic Treatment Is Not Inferior to a Long-Course One in Acute Cholangitis: A Systematic Review. ( 30368681 )
2019
2
Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. ( 30505677 )
2019
3
Efficacy and safety of early cholecystectomy for comorbid acute cholecystitis and acute cholangitis: Retrospective cohort study. ( 30581570 )
2019
4
Early vs late endoscopic retrograde cholangiopancreatography in patients with acute cholangitis: A nationwide analysis. ( 30705731 )
2019
5
Upper gastrointestinal hemorrhage is associated with poor outcomes among patients with acute cholangitis: a nationwide analysis. ( 30741727 )
2019
6
Case of IgG4-associated sclerosing cholangitis with normal serum IgG4 concentration, diagnosed by anti-laminin 511-E8 antibody: a novel autoantibody in patients with autoimmune pancreatitis. ( 30760486 )
2019
7
Biliary Atresia Associated Cholangitis - The Central Role and Effective Management of Bile Lakes. ( 30628982 )
2019
8
Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. ( 30687954 )
2019
9
Caroli Disease Revisited: A Case of a Kidney Transplant Patient With Autosomal Polycystic Kidney Disease and Recurrent Episodes of Cholangitis. ( 30879585 )
2019
10
Cholangiocarcinoma is associated with a raised enhanced liver fibrosis (ELF) score independent of primary sclerosing cholangitis. ( 30762236 )
2019
11
Is recurrent pyogenic cholangitis an independent poor prognostic indicator for resectable intrahepatic cholangiocarcinoma? ( 30274881 )
2019
12
An Original Case of an Association of Eosinophilic Fasciitis with Cholangitis Induced by Nivolumab. ( 30579548 )
2019
13
Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response. ( 30589964 )
2019
14
Beaded bile ducts in primary sclerosing cholangitis. ( 30600377 )
2019
15
The genetics of primary biliary cholangitis. ( 30601157 )
2019
16
Effects of Age and Sex of on Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. ( 30616022 )
2019
17
Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis. ( 30616025 )
2019
18
Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis. ( 30623621 )
2019
19
NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter. ( 30626486 )
2019
20
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. ( 30626829 )
2019
21
Nivolumab-related Sclerosing Cholangitis in Gastric Cancer. ( 30626840 )
2019
22
Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. ( 30632051 )
2019
23
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. ( 30641095 )
2019
24
POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. ( 30643196 )
2019
25
Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. ( 30643240 )
2019
26
Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis. ( 30645706 )
2019
27
Better end points needed in primary sclerosing cholangitis trials. ( 30655632 )
2019
28
Ten-Year Experience in the Prevention of Post-Kasai Cholangitis. ( 30657432 )
2019
29
The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. ( 30661255 )
2019
30
A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. ( 30666146 )
2019
31
Hepatology Elsewhere. ( 30672600 )
2019
32
Baveno-VI-Guided Prediction of Esogastric Varices in Primary Biliary Cholangitis. ( 30676377 )
2019
33
Editorial: liver transplantation for primary biliary cholangitis-the need for timely and more effective treatments. Authors' reply. ( 30689255 )
2019
34
Editorial: liver transplantation for primary biliary cholangitis-the need for timely and more effective treatments. ( 30689256 )
2019
35
CD4+ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T cell receptor repertoires. ( 30690835 )
2019
36
Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 30700999 )
2019
37
Treatment of primary sclerosing cholangitis in children. ( 30705716 )
2019
38
Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker? ( 30709684 )
2019
39
Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis. ( 30713246 )
2019
40
TCRβ Repertoire of Memory T cell Reveals Potential Role for E.coli in the Pathogenesis of Primary Biliary Cholangitis. ( 30721553 )
2019
41
Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. ( 30725292 )
2019
42
Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. ( 30730351 )
2019
43
In vivo 1 H MRS of human gallbladder bile in understanding the pathophysiology of primary sclerosing cholangitis (PSC): Immune-mediated disease versus bile acid-induced injury. ( 30735273 )
2019
44
Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions. ( 30735529 )
2019
45
Autotaxin, Bile Acid Profile and Effect of IBAT Inhibition in Primary Biliary Cholangitis Patients with Pruritus. ( 30735608 )
2019
46
Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. ( 30737815 )
2019
47
Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. ( 30740723 )
2019
48
Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. ( 30772328 )
2019
49
Evolving role of magnetic resonance techniques in primary sclerosing cholangitis. ( 30783369 )
2019
50
Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. ( 30783370 )
2019

Variations for Cholangitis

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Pathways for Cholangitis

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ALB CA2 CRP F2 GGT1 GPT
2 extracellular exosome GO:0070062 9.28 ABCB4 ALB CA2 CEACAM5 F2 FUT2

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.5 CRP IL6 TNF
2 acute-phase response GO:0006953 9.33 CRP F2 IL6
3 positive regulation of neuroinflammatory response GO:0150078 9.26 IL6 TNF
4 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.13 CFTR HLA-DRB1 NR1H4
5 negative regulation of lipid storage GO:0010888 8.8 CRP IL6 TNF

Molecular functions related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bile acid receptor activity GO:0038181 8.62 GPBAR1 NR1H4

Sources for Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....